Currrax Pharmaceuticals over-performed its 2024 revenue goal and has exceeded 50% year-over-year revenue growth for its ...

West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...

Q4 2024 Earnings Call Transcript February 13, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported ...

New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.